Correct no plastic coating, and the pill does absorb in small intestine and if 20% of insulin reaches portal vein we have a home run, but if they change the dose, or delivery system, or have a pill that is taken to temporary kill enzymes or make them not toxic, the pill will not be destroyed. It means full absorption, and we have the best insulin pill in world. Then, we jump to 100.00 per share.
The pill is coated with a plastic film, and that is where the issue sits. For plastic to break down and release the insulin, it not only must be biodegradable, but potentially absorbed into the circulatory system. A repeat of PCBs? So long term trials are mandated before a pill may become reality.
Exactly! Oramed is on many institutional investors radar, perhaps they dont own alot but they are updated and knows whats going on:)
We should have last patient out in July/August and I am wishing for US patent to come soon as a catalyst and trigger buying preassure followed buy results on 2A type 1! Glta
Why don't you check sec filings before you lying?
Institutions are holding 1.3M shares until March 31, that's 16% out of 7.8 total floating shares.
According to the trading activities during the past three months,
the total institutions holding might have been up to 2.5M shares until June 30,
that's 32% of total floating shares. That's called accumulating.
Also watch that 1M shorted shares, it's helping the institutions to do accumulation
and it would have to cover sooner or later.
Revenues driven by recent contracts for the most advanced life saving diagnostics will expand 150 times in the next 24 months. And that is just the beginning!
Millennium Healthcare (MHCC) recently announced newly SIGNED contracts with ACO’s IPA’s and MSO’s to provide exclusive, state-of-the-art, non-invasive cardiovascular and cancer diagnostics to 1,300 locations that will escalate Millennium’s current revenues of $2 million per year to over $300 million per year.
Cardiovascular and cancer diagnostics rolling out to physician’s offices this year.
Revenues will begin rapid growth by year end.
Market size for Millennium Diagnostics is 35,000 primary care offices. The first 1,300 recently contracted with Millennium and the rest are standing in line to sign up with Millennium because:
§ Millenniums program increases physician’s revenues dramatically
§ Millennium’s diagnostics are fully paid by Medicare and are free to patients
§ Millennium’s diagnostics appeal to patients because they are life-saving, fast, painless and highly accurate
§ Millennium’s diagnostics are exclusive from Millennium only
§ The physician pays no up front capital costs
Millennium’s market cap is under $40 million today and shares are selling at under $1.00.
What will this growth do to the price of MHCC shares?
Millennium HealthCare is well positioned for explosive growth that is rarely seen.
Sentiment: Strong Buy
Yup. Institutions like to invest in companies where the head of R&D has been fired twice for operating on the wrong side of the brain multiple times. The CEO's mother (who is the CSO) liquidated her shares.
The bashers will continue to repeat the same story. They never mention the results where placebo and 0801 is compared. In one of the bashing articles, think it was in April/May the author questions why Oramed would hire a surgeon who has no experience in the r&d. Why would they leave out his prior position at Emisphere where he was involved in developing several patents? Why do they not mention that Novo and other companys are using similar methods to protect the insulin? Why do they leave out the background information of M Kidron, that she did not exercise all her options? These bashers are causing damage and uncertainty amongst investors. Anyone holding or looking at buying, do your own due diligence, learn about the company and its story and understand their poduct. Glta
Insulin with the right jell, or capsule, and a different molecular makeup and a explosive , dynamic transport particle, or a drug that suppresses enzymes that is part of the pill will make it easy to be absorbed in small intestine, so this new diabetic pill is a miracle, and the science is getting better day by day so, buy on dips.
Unlikely. Stomach acids destroy the insulin the second it get exposed. In Orameds case its a non altered active compound, normal insulin. Other companys like Novo who develop new kind of insulin with altered molecular structure are up for a challenge. 2b and 3 trial will tell us if it is significant. Thank you for bringing this to our attention. Glta
The "trials" need to be longitudinally significant, and thus could take several years to conduct. Body has a funny way of dealing with digested drugs versus inhaled or injected drugs. Stomach cancer anyone?
Now that he may need fast money for botched surgeries, good time to pump a pie in the sky story via a small company that is located well away from prying eyes. Another Stanley and Pons scam?